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Abstract 
Vaccination has been used to prevent diseases since the early 1800s.Throughout the history of 
vaccination, attention has only been paid to the type of virus that can be administered instead of 
the method of vaccination. Traditional needle-dependent vaccination requires sanitation and 
refrigeration which is not available in developing countries such as India, where viruses such as 
the human papillomavirus (HPV) are very prevalent.  The goal of this study was to develop a 
sublingual wafer formulation that is robust and heat-stable. The sublingual wafer delivery 
method is expected to lower the cost of vaccination because of the ease of transportation and 
storage. Dry powder vaccine formulations were prepared using the Sievers et al patented Carbon 
Dioxide Assisted Nebulization with a Bubble Dryer (CAN- BD) drying process. Excipients 
commonly used in the pharmaceutical industry for oral tablet formation were tested for wafer 
formation with the CAN-BD processed protein powder. Desired wafer properties were tested, i.e. 
binding capabilities, target dissociation time.  
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1. Introduction 
1.1 History of vaccines 
Perhaps the greatest success story in public health is the invention of vaccines. Millions of lives 
were saved and diseases were prevented from wreaking havoc in the body. Human beings have 
benefited from vaccines ever since Edward Jenner’s creation of smallpox vaccine in 1790. Our 
road to discovering effective vaccination is neither neat nor direct. For example, during the 
1830s, a vociferous anti-vaccination movement emerged. Mandatory vaccination was often 
misunderstood. When a Britain passed compulsory vaccination laws in 1821, the working-class 
Britons viewed the mandate as a direct government assault on their communities by the elite 
class.
14
 Although scientist and doctors alike faced irrational protests, they still managed to 
develop many vaccines that would become essential for people around the world.  Dr. Peebles 
was the first to isolate the measles virus and John Franklin Enders was responsible for the 
discovery of the polio virus. With the advent of vaccines, children of the developed nations were 
vaccinated, which contained outbreaks of illness such as smallpox. However, developing 
countries still lack the resources to effectively vaccinate most of the population. This has paved 
the way for research to develop more convenient and cost-effective vaccination method. 
 
1.2 Sublingual Vaccination 
Sublingual vaccination has been used many years to deliver drugs and small molecules to the 
bloodstream. The idea of sublingual vaccination is simple: a form of the vaccine (solution, 
suspension, wafer, film strip, etc.) is placed under the tongue. Due to the presence of high 
density blood vessels in the mucous membranes, the immune system cells capture the vaccine 
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and move the vaccine through the body without significant degradation. According to Dr. Cecil 
Czerkinsky, sublingual vaccination appears to disseminate immunity to a broader range of 
organs than the classical routes of injecting or ingesting vaccines.
7
 Sublingual vaccination 
eliminated the need for the use of needle and the risks associated with the needle injection 
method. Overall, sublingual vaccination matches nasal vaccination in terms of the degree of 
immune response generation
7
; however, the sublingual route did not allow viruses to travel into 
the central nervous system, a rare but potentially harmful complication of intranasal vaccination. 
This hazard of nasal delivery is referred to as cribriform plate penetration. 
1.3 HPV Vaccine  
The human papillomavirus is a leading cause of cervical cancer which is the second most 
common cancer among women in the world. In 2008, there were 529,000 new cases of cervical 
cancer which resulted in 274,000 deaths (WHO 2008).
20
 Cervical cancer is caused by persistent 
genital infection, and, according to the WHO, virtually all of the cervical infection is linked with 
the HPV virus, which is the most common viral infection of the reproductive tract. Although 
present VLP HPV vaccine has demonstrated remarkable efficacy, the high cost of the vaccine 
limit the availability to developing countries where resource are scarce. In 2008, the WHO 
estimated that more than 85% of the cervical cancer deaths are in developing countries. In 
addition to the high cost, the current HPV vaccines are needle-dependent and require 
refrigeration which hinders effective delivery in resource-poor areas
16
. As an alternative to the 
injectable HPV vaccine, the Sievers’s group developed dry vaccine wafers which are thermally 
stable, and convenient for storage and delivery. Due to the wafer’s thermal stability and ease of 
transportation, the cost of the vaccine will be greatly reduced which will enable the vaccine to 
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become available in underdeveloped parts of the world. Several excipients were tested for their 
wafer formation facilitation abilities.  
1.4 Myo-Inositol 
Myo-Inositol constitutes the majority of the placebo HPV powder. It was chosen due to its ability 
to increase viral stability and maintain relatively low hygroscopicity. Inositol is a naturally- 
occurring nutrient found in various forms, the most common being myo-inositol. It is found in 
phospholipids which function as cellular mediators of signal transduction in metabolic regulation, 
and growth. Commercially, it is used in baby formula and derived from rice. Excipients that are 
plant derived from rice. Excipients that are plant-derived rather than animal-derived have the 
advantage of being free from hazardous contaminants. 
 
1.5 Excipients Utilized 
Four excipients were tested but only 2 were ideal for wafer formulation. Microcrystalline 
Cellulose (MCC) and (hydroxypropyl) methyl cellulose (HPMC) were able to aid wafer 
formation when they were present in relatively small amount. Both compounds are known 
pharmaceutical excipients. Microcrystalline cellulose is purified, partially depolymerized 
cellulose that is prepared by treating alpha-cellulose. MCC consists of crystalline aggregates 
Figure 1. Structure of myo-Inositol from Sigma Aldrich 
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which are obtained through hydrolytic degradation of unpurified region of the cellulose polymer. 
As an insoluble fiber, microcrystalline cellulose (MCC) does not get absorbed into the 
bloodstream; hence, it does not cause toxicity when taken orally
17
. The biggest disadvantage of 
the MCC is its low water-solubility
10
. Wafers that contain high amounts of MCC may 
demonstrate slow dissolution time. However, for this study, MCC content can be as little as 20% 
of the wafer mass, which is sufficient for robust wafer formation. 
       (Hydroxypropyl) methylcellulose (HPMC) is the other excipient that aided in wafer 
formation. HPMC is a non-ionic, water-soluble polymer that is derived from cellulose. In 
addition to pharmaceutical usage, HPMC is employed for making cement renders, ophthalmic 
Figure 3. Microcrystalline Cellulose  
provided by Sigma Aldrich 
Figure 2 (Hydroxypropyl) methylcellulose 
provided by Sigma Aldrich 
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lubricant, eye drops, etc.  Benefits of using this excipient include its reversible gelation upon 
heating; HPMC is surface active and enzyme resistant. Hydrophilic polymer such as HPMC 
interacts with water via their hydroxyl groups. Water can plasticize the HPMC through hydrogen 
bonding which results in strong and compact formation which is very favorable for 
manufacturing sublingual wafer tablet by direct compression.
11, 13 
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2-Experimental 
2.1 Formulation tested 
Four excipients were tested: Polyvinylpyrrolidone(PVP), HPMC, MCC, Corn Starch (high 
amyolose). Each formulation had different amount of excipients ranging from 20%-50% of the 
total wafer mass. The placebo HPV powder consisted of 98.5% Myo-Inositol and 1.5% Leucine, 
with a trace amount of ammonium acetate in order to improve respiratory fractions. Formulations 
that showed robust wafer formation were tested with lower excipient content. For example, the 
ability to produce robust wafers from 50% to 20% excipient content was continuously 
demonstrated by the MCC. However, the ability to produce robust wafers at 40% make up of 
total wafer mass was not successfully demonstrated by the PVP excipient; hence, no trials were 
conducted at lower excipient content. 
      
2.2 Experimental apparatus. 
Wafers were made with the KBr Port-A-Press Kit from the International Crystal Laboratories 
(Figure 4). A wrench was used to ensure that the same amount of pressure was applied to each 
pellet, thereby facilitating reproducibility of result. The wrench also ensured easy tweaking of 
the applied pressure. A strain gauge panel meter from Omega was attached to the pellet press to 
ensure accurate reading of results (Figure 5). 
Placebo Powder was dispensed into a 4mm-sized die for compression ( Figure 4). The 4mm 
wafer served to mimic the wafer size that will be tested during clinical trial.  
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Placebo powder was introduced into the die with a wafer dispensing device (Figure 6) that was 
developed by Dr. Stephen Cape. The device dispenses a consistent mass of powder to the die, 
thereby facilitating the manufacture of wafers with masses in a narrow range. During the 
production of wafers, the pellet press was placed in a Terra Universal glove box in which the 
relative humidity (%RH) of the environment can be adjusted. The glove box served as a 
humidifying chamber during the dry, winter season in Colorado. Water vapor and nitrogen gas 
were simultaneously pumped into the chamber to keep the relative humidity at a constant level 
which minimized the effect of humidity fluctuation in the lab. The glove box is made of static-
dissipative PVC plating which reduces the effect of static forces between the micrometer-sized 
particles in the placebo powder. Static between particles negatively influenced wafer robustness. 
 
 
Figure 4 Pellet press and die set for wafer making 
(Provided by http://www.internationalcrystal.net/, 
visited on March 19
th
, 2012 
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Figure 5  Strain gauge panel . (Image provided by 
gauhttp://www.omega.com/pressure/psc.html, visited 
March 18
th
, 2012 
Figure 6. Powder dispensing device that was invented by Dr. Stephen 
Cape for the use of loading in the die a consistent amount of powder 
for wafer making. 
9 
 
2.3 Materials 
The excipients tested for this study were: microcrystalline cellulose, (hydroxypropyl) 
methylcellulose with a viscosity of 100 centipoise (CP), polyvinylpyrrolidone of 10k molecular 
weight, and corn starch with trace amylose. The MCC used for this study was from Arcos 
Organics with an average particle size of 50µm. The rest of the excipients were obtained from 
Sigma Aldrich. The polyvinylpyrrolidone used for this study did not come as fine-sized particles 
therefore milling of the particle was required. The morphology of the milled and un-milled PVP 
was captured by using a scanning electron microscope (Figures 8, 9). The placebo powder for the 
HPV vaccine consisted of myo-inositol from Tsuno Rice Fine Chemicals (Katsuragi, Japan) 
(Figure 7) in addition to L-leucine. The placebo HPV powder was manufactured by Dave 
McAdams with the CAN-BD process (1200 psi CO2, 65 
o
C, 0.3 mL/min H2O flow rate). 
   
        
Figure 7 Scanning electron microgram of unprocessed 
myo-inositol (Tsuno). Magnification-200x, Bar=100µM 
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Figure 9 Scanning electron microgram of milled 
polyvinylpyrrolidone. Magnification=200X. 
Bar=100µM 
Figure 8. Scanning electron microgram of unmilled 
polyvinylpyrrolidone. Magnification=200x, Bar=100µM  
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2.4 Dissolution Equipment and Method 
The dissolution properties of wafers were tested. A scintillation vial filled with 3 mL of water at 
37
o
 C (simulation of salivary temperature) was used to dissolve the vaccine wafers. No stirring or 
shaking of the dissolution vials was required. The water was kept in a warm water bath. Before 
every trial, the temperature was measured in order to confirm that it was at 37
o
 C. 
 
2.5 Preparation of Wafer Formulation and Manufacturing of Wafers 
When the formulations were produced, excipients and placebo powders were milled then they 
were thoroughly mixed with a vortex mixer. This was done in order to avoid uneven distribution 
of different excipients which would yield misleading results. As the wafers were made, the pellet 
press was held at the desired pressure for 30 seconds as a mean of improving wafer integrity.  
Towards the beginning of the study, wafers were made at a humidity of 22±1 % relative 
humidity. However, wafers made under this condition only had a deceivingly robust appearance. 
When those wafers were transferred from vial to vial by using a pair forceps, crumbling of the 
wafers occurred. In order to solve this problem, more excipients were added into the formulation.  
Dr. Stephen Cape suggested that making wafers at a higher humidity would improve wafer 
integrity without the need to add more excipient. Subsequently, wafers were manufactured at 
40 %RH environment. Initially wafers would be made at 22 %RH and be left in a humidity 
chamber that was set at 40 %RH for 20-50 minutes. However, employing this method did not 
produce more robust wafers than wafers made from the original method.  
12 
 
Another method involved leaving formulated powder at 40 %RH for 20 minutes; then wafers 
were made at 40 %RH conditions. The powder was noticeably stickier, and the wafers made 
from these powders were very robust even when a relatively low pressure was applied (20lb). 
During subsequent trials, placebo powders were exposed to a 50%-60 %RH environment for 20 
minutes before wafers were made. 
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3-Results 
3.1 Characterization of wafers 
All the wafers made were scored with a number to characterize their robustness, with 1 being the 
least robust, to 6 being the most robust (Figure 10).  
 
 
3.2 Factors Affecting Wafer Robustness 
Humidity, applied pressure, and excipient content were all adjusted to test their relative effect on 
the wafer’s robustness. The placebo powder’s ability to form wafers without additional 
excipients was tested, and no robust wafers were formed. The placebo wafers with no excipients 
had an integrity ranging from 1-2 (Table 2). For each formulation, the higher the applied 
pressure, the more robust the wafer will be (Figure 14). In addition, added moisture content to 
the wafers compensated for low applied pressure. For example, at a pressure of 20 lb and 20% 
Wafer Integrity Scale 
6                       5                   4                  3                   2                  1 
Figure 8. Image of wafers at different assigned integrity level 
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RH humidity level, wafers made from different formulations can be described as having a 
deceivingly robust appearance. These wafers would generally crumble when being transferred 
with a pair of forceps. At 20 %RH, a pressure of 85 lb. of force was sufficient in producing a 
wafer with robust integrity. At 50 %RH, robust wafers can be made by applying as little as 20 lb. 
of force (Table 6). The amount of excipients that were present in a wafer also increases wafer 
robustness (Figure 12). Lastly, the mass of the wafers did not seem to have a significant effect on 
wafer integrity (Figure 11).  
3.3 Factors affecting wafer disintegration 
The content of excipients is one of the primary factors that affect wafer disintegration time. 
Although the original intent was to test wafer’s dissolution properties, none of the wafers that 
were produced for this study completely dissolved, instead, the wafers disintegrated into small 
particles, therefore, disintegration properties were observed and recorded. Robust wafers needed 
to disintegrate in a reasonable amount of time (under 2 minutes) to be practically useful. 
Formulations that disintegrated too slowly (requiring >2 minutes) were not deemed as a viable 
option. PVP measured to have the slowest disintegration time whereas MCC and the mixture of 
HPMC and MCC were measured to have short(less than 30 seconds) disintegration time. The 
pressure applied had minimal effect on the dissolution time of the wafer (Figure 15), in addition, 
the wafer mass also did not significantly affect the dissolution time.  
3.4 Viable Formulations 
The microcrystalline cellulose and the 33% HPMC, 66% CMC mixture were demonstrated to 
have the best wafer vaccine characteristics. Both formulations disintegrated in less than 30 
seconds and can be made into a robust wafer with an applied pressure of 30 lb. or less. Most 
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importantly, the two excipient formulations only required approximately 20-30% of the wafer 
mass to produce a robust wafer (Table 1), which allowed for maximal amount of active vaccine 
protein content to be present in the wafer.  
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Figure 11.  Average wafer integrity based on wafer mass. Errors bars indicate one 
standard deviation from the mean 
Figure 12. Average wafer integrity in relation to percent excipients in wafer mass. 
Errors bars indicate one standard deviation from the mean 
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Figure 13.  Wafer Integrity in relation amount of pressure applied  
Figure 14.  Wafer Integrity in relation to the percent of moisture in the 
environment where the wafers are made. 
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Figure 15. Disintegration time of wafers in relation to pressure applied in 3 mL of 
37
o
 C water 
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Table 1 Dry Powder Optimization
 
1Dissolution tests were conducted with 3mL of 35.5-37.0o C water. 
2Wafer robustness was assessed as low, medium and high. Low signifies a poorly formed wafer where it 
is unable to stay intact.  Medium robustness represents wafers that stayed intact but may have small 
chunks coming off during transferring.  High robustness indicates a wafer that is intact with little to no 
loose powder coming off.  
 
 
Dry Powder Composition Excipients for Wafer Formation Processing Conditions Wafer Robustness2
Average 
Dissolution Time1
70 atm compression pressure
6-8% RH
30 seconds compression time
4-mm die set used
175 atm compression pressure
10% RH
30 seconds compression time
4-mm die set used
350 to 440 atm compression pressure
20% RH
30 seconds compression time
4-mm die set used
35 to 70 atm compression pressure
50-70% RH
30 seconds compression time
4-mm die set used
70 to 140 atm compression pressure
50-70% RH
30 seconds compression time
4-mm die set used
35 to 70 atm compression pressure
50-70% RH
30 seconds compression time
4-mm die set used
35 to 70 atm compression pressure
50-70% RH
30 seconds compression time
4-mm die set used
97% myo -inositol, 
1.5% leucine,
1.5% bovine serum albumin
Microcrystalline cellulose 
(33% of total wafer mass) with 
hydroxypropylmethyl cellulose 
(17% of total wafer mass)
Medium 60-90 Seconds
420-460 seconds
(7-8 minutes)
98.5% myo -inositol, 
1.5% leucine
Microcrystalline cellulose 
(33% of total wafer mass) with 
hydroxypropylmethyl cellulose 
(17% of total wafer mass)
High 60-90 seconds
97% myo -inositol, 
1.5% leucine,
1.5% bovine serum albumin
Microcrystalline cellulose 
(33% of total wafer mass)
High 20-23 seconds
98.5% myo -inositol, 
1.5% leucine
Starch (from corn with high amylose) 
(50% of total wafer mass)
Low 10-15 seconds
98.5% myo -inositol, 
1.5% leucine
Microcrystalline cellulose 
(30% of total wafer mass)
High 16-20 seconds
98.5% myo -inositol, 
1.5% leucine
Sorbitol 
(50% of total wafer mass)
Medium 80- 88 seconds
98.5% myo -inositol, 
1.5% leucine
Polyvinylpyrrolidone 
(50% of total wafer mass)
Medium
19 
 
 
Table 2 Placebo Powder Wafer Characterization 
 
 
 
 
 
 
 
 
 
 
 
 
Vial EmptyVial  Mass (g) FullVial Mass(g) Wafer Mass(g) Pressure(psi) Humidity Wafer Integrity
1 5.70125 5.72996 0.02871 200 11 2
2 5.74651 5.79069 0.04418 200 9.1 1
3 5.68954 5.774453 0.084913 200 8 2
4 5.67013 5.7084 0.03827 300 6.6 1
5 5.72156 5.76933 0.04777 300 13 2
6 5.69906 5.74437 0.04531 300 9.5 2
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4-Discussion 
The primary objective of this study was to develop a wafer formulation that is robust and can 
disintegrate in water (surrogate for saliva) in a reasonable amount of time. The robustness of a 
wafer is usually proportional to the amount of excipient added. The placebo powder does not 
exhibit adhesive properties because the placebo powder was designed to have micro particles 
which do not agglomerate during dry powder inhalation. Ammonium acetate was also added in 
order to improve respiratory fractions. This eliminated the option of developing a placebo protein 
powder that contains adhesive characteristics. 
During relatively hot (~80
o
C) and humid conditions (<60 %RH), the placebo (DM110708) 
powder formed clumps which could have been due to the high relative humidity in the laboratory. 
The placebo powder is mainly composed of myo-inositol which contains 6 polar hydroxyl groups. 
The relative high moisture may have induced hydrogen bonding between the myo-inositol 
particles.
18
 
Excipients that possessed more polymer-like properties were chosen to improve wafer robustness; 
however, there is the chance that the robust wafer might not disintegrate in an acceptable time-
frame. The initial tests with polymers were conducted with polyvinylpyrrolidone, although it is a 
water soluble polymer, no complete dissolution occurred, however, complete disintegration in 3 
mL of 37
o
 C water could take up to 4-6 minutes, which may be too long for efficient absorption 
under the tongue. A more hydrophilic polymer was desired in order to ensure timely dissolution. 
Dr. Stephen Cape has suggested microcrystalline cellulose as an option. MCC is known for its 
low solubility,
10
 however, the MCC-placebo wafers all disintegrated within 30 seconds during 
dissolution testing. Dry mixing the hydroxyl propyl methyl cellulose also yielded robust wafers; 
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however, the disintegration time is around 2-3 minutes which may not be fast enough for wafer 
disintegration, although this is still being evaluated. The idea behind mixing the HPMC and 
MCC was to have the MCC help the wafer dissolve in time while the HPMC holds the wafer 
together under low pressures. However, extensive trials showed that wafers formed from the 
MCC excipients and the wafers formed from the HPMC -plus MCC mixture had similar 
robustness. 
Pressure was applied to the powder mixtures in order to make them robust; however, the active 
protein or viral envelope in the vaccine may lose activity under high pressure. Studies were done 
to demonstrate the correlation between protein unfolding and high pressure
19
. Wafers were 
exposed to moisture, which can further enhance binding properties of the polymer excipients
12
,
 
in 
order to reduce the amount of pressure applied. However, moisture is also known to destabilize 
proteins as the hydrophilic exterior interacts with water, which also can result in protein 
unfolding
18
. This possible effect of moisture was minimized by drying out the wafer overnight 
with desiccants in a sealed vacuum pack. Karl Fischer titration was done on wafers in order to 
ensure that the wafers did not contain excessive moisture content. The moisture content of was 
determined to be around 0.08%-0.13%.  
Upon disintegration, wafers that contain different excipients formed various kind of solution. 
The viscosity of solutions of HPMC was high because it is often used as a thickener. Sigma 
Aldrich product literature indicates that HPMC solubility is around 10mg/ml, but the water 
temperature needs to be 90 C
o
, stirring and agitation is also required. MCC, on the other hand, 
dissociates into micro particles, however, it does not go into solution which maybe less 
conducive for absorption under the tongue.  
22 
 
In the section describing method used, it was mentioned that formulated powder which was left 
exposed to moisture formed better wafers than wafers that were exposed to moisture after they 
have already been made. This was due to the greater surface area for moisture exposure when 
exposing the powder before making the wafers
12
. In addition, moisture is spread evenly among 
the micro particles. The method where wafers were exposed to moisture after its formation only 
coats the outside of the wafer where the inside may remain dry and brittle. Karl Fischer was done 
on wafers made from the 2 methods where wafers were exposed to moisture and placebo powder 
was exposed to moisture before wafers were made. The difference in moisture content was only 
4-6% where this difference in moisture content should not be significant enough to cause a 
difference in protein stability.  
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5-Conclusion 
Through extensive trials during this study, two formulations was chosen: 70% (myo-Inositol, 
Leucine, ammonium acetate) and 30% MCC; 60% (myo-Inositol, Leucine, ammonium acetate) 
and 40% (2/3 HPMC, 1/3 MCC.) These two formulations performed satisfactorily both in wafer 
quality testing and dissolution tests. These two formulations can be made at 40% moisture 
conditions which, after Karl Fischer testing, do not add too much moisture to the wafer itself. 
This lessens the possibility of protein destabilization.  
Although this study was primarily aimed toward application in HPV vaccine development, the 
sublingual wafer form of vaccines may be applied to other diseases such as the measles. If 
clinical trial results demonstrate that the efficacies of sublingual wafer vaccines are comparable 
to that of the needle-injected form, the sublingual form may be a solution for vaccination in 
underdeveloped regions of the world. The research on sublingual wafer formulation signals a 
new direction in vaccine research which may make vaccination more affordable, and efficient.  
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Appendix 
Table 3 Microcrystalline Cellulose Wafer Characterization with 40% Cellulose Microcrystalline 
as Wafer Mass 
 
                
Table 4 .Microcrystalline Cellulose Wafer Characterization with 30% Cellulose Microcrystalline 
as Wafer Mass 
 
 
 
C1 6.32724 6.33352 100 6 513
C2 6.35999 6.36761 100 6 475
C3 6.31315 6.32279 100 6 490
C4 6.29996 6.31063 80 5 460
C5 6.31854 6.32756 80 5 455
C6 6.36231 6.37109 80 5 480
Powder Content: 70% DM100308, 30% Cellulose Microcrystalline 50uM
Wafer Making Condition: Humidity-13% RH, 4mm die, kept at tested pressure for 30 seconds
Dissolution Condition: 3mL wafer,  water temp: 35.0 C- 37 C
Sample Empty(g) Full(g) Pressure(lb) Wafer Integrity Dissolution Time(sec)
F1 6.30428 6.31297 60 4 N/A
F2 6.33597 6.34509 60 4 N/A
F3 6.29178 6.30026 60 4 N/A
F4 6.34655 6.35538 80 4 N/A
F5 6.31245 6.32265 80 4 N/A
F6 6.35204 6.36422 80 4 N/A
Powder Content: 60% DM110308 , 40% Cellulose Microcrystalline (50uM)
Wafer Making Condition: Humidity-13% RH, 4mm die, kept at tested pressure for 30 seconds
Dissolution Condition: 3mL wafer,  water temp: 35.0 C- 37 C
Sample Empty(g) Full(g) Pressure(lb) Wafer Integrity Dissolution Time(sec)
J7 6.16244 6.17031 85 6 35
J8 6.22717 6.23123 85 6 30
J9 6.18541 6.19301 85 5 29
J10 6.18628 6.19528 100 4                                      N/A
J11 6.17517 6.18318 100 5 20
J12 6.18457 6.19301 100 5 21
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Table 5 Microcrystalline Cellulose Wafer Characterization with 40%  as Cellulose  
Microcrystalline  as Wafer Mass  at  an  Exposed Humidity of  40% RH 
 
 
 
Table 6 Microcrystalline Cellulose Wafer Characterization with 50% as Cellulose 
Microcrystalline as Wafer Mass 
 
 
Powder Content: 60% DM110308 , 40% Cellulose Microcrystalline (50uM)
Wafer Making Condition: Humidity-40% RH, 4mm die, kept at tested pressure for 30 seconds
Dissolution Condition: 3mL wafer,  water temp: 35.0 C- 37 C
Sample Empty(g) Full(g) Pressure(lb) Wafer Integrity Dissolution Time(sec)
Z1 6.59829 6.60402 40 6 Instant
Z2 6.55061 6.55685 40 6 Instant
Z3 6.58216 6.59264 30 6 Instant
Z4 6.49783 6.50405 40 6 Instant
Z5 6.53815 N/A 30                         N/A Instant
Z6 6.41846 6.42391 40 6 Instant
Z7 6.60324 6.60972 30 5 Instant
Z8 6.50961 6.50743 30 6 Instant
Z9 6.61708 6.62291 30 6 Instant
Z10 6.53721 6.54545 40 6 Instant
Z11 6.48279 6.49156 40 6 Instant
Z12 6.55291 N/A 30                         N/A Instant
Powder Content: 80% DM110308 , 20% Microcyrstalline Cellulose
Wafer Making Condition: Humidity-50% RH, 4mm die, kept at tested pressure for 30 seconds
Dissolution Condition: 3mL wafer,  water temp: 35.0 C- 37 C
Sample Empty(g) Full(g) Pressure(lb) Wafer Integrity Dissolution Time(sec)
X1 6.17301 6.18401 20 6 Instant
X2 6.23274 6.24521 20 6 Instant
X3 6.26265 6.27821 20 6 Instant
X4 6.19648 6.20459 20 6 Instant
X5 6.25059 6.26105 20 6 Instant
X6 6.20125 6.21145 20 6 Instant
X7 6.24616 6.25606 10 4 Instant
X8 6.15557 6.15857 10 4 Instant
X9 6.19921 6.20154 10 4 Instant
X10 6.32228 6.32229 10 3 Instant
X11 6.26526 6.27811 10 4 Instant
X12 6.20767 6.21524 10 3 Instant
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Table 7 (Hydroxypropyl)Methylcellulose Wafer Characterization with 50% HPMC as Wafer 
Mass 
 
 
Table 8 Polyvinylpyrrolidone Wafer Characterization with 50% Polyvinylpyrrolidone as Wafer 
Mass 
 
\ 
 
 
Powder Content: 50% DM110308 , 50% HPMC 100CP
Wafer Making Condition: Humidity-20% RH, 4mm die, kept at tested pressure for 30 seconds
Dissolution Condition: 3mL wafer,  water temp: 35.0 C- 37 C
Sample Empty(g) Full(g) Pressure(lb) Wafer Integrity Dissolution Time(sec)
A1 6.33881 6.34653 100 6 163
A2 6.32163 6.32768 100 6 175
A3 6.35763 6.36541 100 6 150
A4 6.32565 6.33398 125 6 170
A5 6.32981 6.33623 125 6 180
A6 6.31761 6.32616 125 6 163
Powder Content: 50% {Myo(95%)-Leucine(5%)}, 50% PVP High Molecular Weight    20%RH
Dissolution Condition: 3mL water, water temp-23C
Vial Empty(g) Full(g) Wafer(g) Pressure(lb) Die Size(mm) Wafer Integrity Dissolution Time
A 6.31977 6.36888 0.04911 100 7 4 8 min 39 sec
B 6.35781 6.39018 0.03237 100 7 2 8 min 22sec
C 6.33999 6.38843 0.04844 100 7 6 7 min 15 sec
D 6.40749 6.44594 0.03845 100 7 6 9 min 08 sec
E 6.38951 6.43391 0.04441           WGNM* 7 2 8 min 56 sec
F 6.29039 6.33272 0.04233           WGNM* 7 6 7 min 56 sec
G 6.41472 6.45008 0.03536           WGNM* 7 2 7 min 12 sec
H 6.36644 6.42125 0.05481           WGNM* 7 3 9 min 30 sec
I 6.28718 6.29645 0.00927 50 4 6 6 min 27 sec
J 6.36221 6.36961 0.00741 50 4 6 5 min 41 sec
K 6.31329 6.31952 0.00623 50 4 6 5 min 20 sec
L 6.37494 6.38618 0.01124 50 4 6 6 min 13 sec
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Table 9 Polyvinylpyrrolidone Wafer Characterization with 60% PVP as Wafer Mass 
 
Table 10 Polyvinylpyrrolidone Wafer Characterization with 55% PVP as Wafer Mass 
 
 
 
 
 
 
 
Powder Content: 40%[ Myo(98.5%)-Leucine(1.5%)], 60% PVP High Molecular Weight
Date: Oct 28th, 2010 Humidity: Under 10% RH   Die size: 4mm
Vial Empty(g) Full(g) Wafer(g) Pressure(lb) Wafer Integrity Dissolution Time
C1 6.29263 6.320271 0.02764 50 2 4 min 34 sec
C2 6.38587 6.40155 0.01568 50 6 3 min 42 sec
C3 6.33664 6.34963 0.01299 50 6 3min 59sec
C4 6.36432 6.37671 0.01239 WGNM 4 4 min 09 sec
C5 6.3445 6.35432 0.00982 WGNM 6 5 min
C6 6.33471 6.34481 0.01012 WGNM 6 4 min 3 sec
Powder Content 55% PVP Low Molecular Weight  45% Myo(CAN-BD)  Die Size: 4mm
Date: Oct 21st, 2010 Humidity: Under 10%RH
Vial Empty(g) Full(g) Wafer(g) Pressure(lb) Wafer Integrity Dissolution Time
A1 6.40265 6.41009 0.00744 75 1 4 min 5 sec
A2 6.33966 6.34661 0.00695 75 1 4 min 15sec
A3 6.35792 6.36558 0.00766 75 1 4 min 6 sec
A4 6.40308 6.41007 0.00699 75 1 2 min 20 sec
A5 6.37863 6.38898 0.01035 150 3 4 min 36 sec
A6 6.36839 6.37124 0.00285 150 4 4 min 4 sec
A7 6.39497 6.34028 0.00345 150 3 4 min 10 sec
A8 6.34444 6.34944 0.00611 150 3 2 min 35 sec
